文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

地塞米松滴眼液治疗早产儿视网膜病变:基于瑞典登记数据的双重差分研究

Treating Retinopathy of Prematurity with Dexamethasone Eye Drops: A Difference-in-Differences Study in Sweden Using Register Data.
PubMed 文献 · Ophthalmology · 2025-09-30

这项基于瑞典早产儿视网膜病变质量登记数据的队列研究,纳入2015—2018年(对照年份)和2020—2021年(干预年份)在4个瑞典中心登记的胎龄不足30周的早产儿,比较了引入地塞米松滴眼液的干预中心与3个对照中心两个时期需传统治疗的ROP比例。在严重ROP患儿中,干预中心由23/32(72%)降至4/32(13%)(P < 0.001),3个对照中心由82/175(47%)变为32/57(56%)(P = 0.22);校正交互比值比为0.05(95%CI 0.01-0.22;P < 0.001)。作者认为及时使用低剂量地塞米松滴眼液可能减少需传统治疗的严重ROP患儿比例,但需进一步研究证实。

要点

  • 严重ROP患儿中,干预中心需传统治疗比例由72%(23/32)降至13%(4/32),对照中心由47%(82/175)升至56%(32/57)。
  • 全部筛查婴儿中,干预中心由5.6%(23/409)降至1.8%(4/217),对照中心由8.6%(82/950)降至7.3%(32/441)。
  • 严重ROP患儿校正交互比值比为0.05(95%CI 0.01-0.22;P < 0.001)。

核心结论

  • 在严重ROP婴儿人群中,引入地塞米松滴眼液与需传统ROP治疗的婴儿比例显著下降相关。
  • 作者认为,及时给予低剂量地塞米松滴眼液可能作为一种简单、经济、无创的干预,减少全球严重视力损害的主要原因之一。
  • 作者指出需进一步研究以证实上述发现。

研究设计与样本

  • 基于登记的队列研究,使用瑞典ROP质量登记数据。
  • 纳入2015—2018年(对照年份)和2020—2021年(干预年份)在4个瑞典中心登记的胎龄不足30周的早产儿。
  • 4个中心中1个为干预中心,在较晚时期诊断2型ROP时开始使用地塞米松滴眼液。
  • 比较引入与未引入地塞米松滴眼液的中心在两个时期传统ROP治疗(激光消融或玻璃体腔注射抗VEGF)的频率,分析对象包括严重ROP婴儿和全部纳入婴儿。
  • 采用双重差分统计方法。

主要发现

  • 干预中心严重ROP婴儿需传统ROP治疗的比例由23/32(72%)降至4/32(13%)(P < 0.001)。
  • 干预中心全部筛查婴儿中该比例由23/409(5.6%)降至4/217(1.8%)(P = 0.03)。
  • 3个对照中心严重ROP婴儿中由82/175(47%)变为32/57(56%)(P = 0.22)。
  • 3个对照中心全部筛查婴儿中由82/950(8.6%)变为32/441(7.3%)(P = 0.38)。
  • 严重ROP婴儿的双重差分分析校正交互比值比为0.05(95%CI 0.01-0.22;P < 0.001),提示干预中心传统ROP治疗发生率的下降幅度明显更大。

关键数值与推荐

  • 主要结局指标为各组需传统ROP治疗的婴儿比例及校正潜在混杂因素后的交互比值比。
  • 严重ROP婴儿校正交互比值比0.05(95%CI 0.01-0.22;P < 0.001)。

临床怎么用

  • 原文结论指出,及时给予低剂量地塞米松滴眼液可能作为减少需传统治疗的严重ROP的简单、经济、无创干预,并指出需进一步研究证实。

局限性

  • 作者指出需进一步研究以证实上述发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To estimate the effect of dexamethasone eye drops on the risk of progression from type 2 retinopathy of prematurity (ROP) to ROP requiring traditional treatments. DESIGN: Register-based cohort study. PARTICIPANTS: Preterm infants born before 30 weeks' gestation from 2015-2018 (control years) and from 2020-2021 (intervention years) registered in the Swedish Quality Register for ROP at 4 Swedish sites were included. In 1 of these sites, the intervention site, topical dexamethasone was introduced during the later period when type 2 ROP was diagnosed. METHODS: The frequency of traditional ROP treatments (laser ablation or intravitreal injection of anti-VEGF) was compared between the 2 periods at sites that had and had not introduced topical dexamethasone during the later period. Analyses were conducted both on infants with severe ROP and on all included infants. The difference-in-differences statistical method was used. MAIN OUTCOME MEASURES: The proportion of infants that required traditional ROP treatment in each group and the interaction odds ratio, adjusted for potential confounding factors. RESULTS: At the intervention site, the incidence of traditional ROP treatment fell from 23/32 (72%) to 4/32 infants (13%; P < 0.001) with severe ROP and from 23/409 (5.6%) to 4/217 screened infants (1.8%; P = 0.03). For the 3 control sites, the equivalent numbers were from 82/175 (47%) to 32/57 infants (56%; P = 0.22) and from 82/950 (8.6%) to 32/441 infants (7.3%; P = 0.38). The difference-in-differences analyses resulted in an adjusted interaction odds ratio of 0.05 (95% confidence interval, 0.01-0.22; P < 0.001) for infants with severe ROP, suggesting a markedly larger decline in occurrence of traditional ROP treatments at the intervention site. CONCLUSIONS: In this population of infants with severe ROP, the introduction of dexamethasone eye drops was associated with a significant reduction in the proportion of infants requiring traditional ROP treatments. A timely administration of low-dose dexamethasone eye drops may serve as a simple, cost-effective, and noninvasive intervention to reduce one of the leading causes of severe visual impairment worldwide. Further studies are needed to confirm our findings. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Gränse LAKC, Öhnell HMV, Holmström G, et al. Treating Retinopathy of Prematurity with Dexamethasone Eye Drops: A Difference-in-Differences Study in Sweden Using Register Data. Ophthalmology. 2025. PMID: 41038455. doi:10.1016/j.ophtha.2025.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。